ArticleBiogerontology2026
A multi-ingredient food supplement slows age-dependent decline of mobility and influences gene expression in C. elegans.
Article in Biogerontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of developing interventions to slow ageing is not only lifespan extension but more importantly to increase healthspan, the period of life spent in active good health. Nutritional interventions have emerged as a potential strategy to maintain health with age. Testing these interventions for effects on human ageing would take several years and require large cohort sizes. We therefore employed C. elegans as a rapidly ageing model organism to investigate the effects of two commercially available nutrition-based products on ageing-related decline of mobility as an indication of healthspan. These products are multi-ingredient formulations comprising vitamins, minerals, antioxidants, amino acids and botanical extracts. They include compounds expected to positively influence ageing such as Dihydronicotinamide mononucleotide, NAD + booster, trans-resveratrol, taurine, pterostilbene and bioflavonoids. V14™ contains 40 + ingredients and AG1® contains 70 + ingredients with 5 additional probiotic strains. Mobility-based readouts over time were obtained using WormGazer™ imaging technology. Worms exposed to V14™ showed increased movement and speed with age compared to those exposed to AG1® and to a solvent control. To investigate the underlying mechanisms, transcriptomic profiling was performed on V14™ exposed worms, revealing modulation of pathways involved in metabolism and stress responses, processes associated with ageing. Collectively, these findings suggest that V14™ delays age-related decline in C. elegans and highlight the potential of targeted nutritional interventions to modulate pathways relevant to human ageing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.